Table 1.

Baseline characteristics of trial subjects

Characteristic	Iloprost (n = 75)	Placebo (n = 77)	Iloprost: former smoker (n = 35)	Placebo: former smoker (n = 36)	Iloprost: current smoker (n = 40)	Placebo: current smoker (n = 41)
Sex of subject–No. (%)
Female	23 (30.7)	19 (24.7)	8 (22.9)	9 (25.0)	15 (37.5)	10 (24.4)
Male	52 (69.3)	58 (75.3)	27 (77.1)	27 (75.0)	25 (62.5)	31 (75.6)
Race of subject–No. (%)
Black	4 (5.3)	8 (10.4)	0 (0.0)	3 (8.3)	4 (10.0)	5 (12.2)
Other	2 (2.7)	3 (3.9)	1 (2.9)	0 (0.0)	1 (2.5)	3 (7.3)
White	69 (92.0)	66 (85.7)	34 (97.1)	33 (91.7)	35 (87.5)	33 (80.5)
Age, y	57.6 ± 10.6	58.3 ± 8.6	61.5 ± 10.7	61.2 ± 9.6	54.2 ± 9.2	55.7 ± 6.8
Smoker years	34.6 ± 10.5	36.0 ± 10.0	32.3 ± 10.1	33.0 ± 10.2	36.6 ± 10.5	38.7 ± 9.0
Packs per day	1.5 ± 0.6	1.4 ± 0.5	1.8 ± 0.7	1.4 ± 0.5	1.3 ± 0.4	1.3 ± 0.6
Pack years	51.8 ± 26.8	49.9 ± 26.3	56.4 ± 29.6	48.7 ± 27.0	47.8 ± 23.7	50.9 ± 26.0
Smoker quit years			12.0 ± 8.4	12.0 ± 10.0
FEV1	2.4 ± 0.9	2.3 ± 1.0	2.4 ± 0.9	2.3 ± 1.0	2.5 ± 0.9	2.4 ± 0.9
FEV/FVC ratio	0.7 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.7 ± 0.2	0.7 ± 0.1	0.7 ± 0.1
Sputum cytology	4.4 ± 0.7	4.4 ± 0.6	4.4 ± 0.6	4.3 ± 0.5	4.4 ± 0.8	4.5 ± 0.7
Average histology	2.6 ± 1.1	2.5 ± 1.1	2.1 ± 1.0	2.0 ± 1.1	3.0 ± 1.1	2.9 ± 0.9
Maximum histology	4.3 ± 1.5	3.8 ± 1.6	3.6 ± 1.8	3.1 ± 1.8	4.8 ± 0.9	4.5 ± 1.1
Dysplasia index	33.3 ± 28.7	32.8 ± 31.1	20.4 ± 22.2	21.3 ± 28.5	44.6 ± 29.2	42.8 ± 30.1
Maximum histology–No. (%)
No dysplasia (grades 1–3)	16 (21.3)	22 (28.6)	13 (37.1)	18 (50.0)	3 (7.5)	5 (12.2)
Mild (grade 4)	14 (18.7)	15 (19.5)	7 (20.0)	5 (13.9)	7 (17.5)	10 (24.4)
Moderate (grade 5)	33 (44.0)	35 (45.5)	10 (28.6)	12 (33.3)	23 (57.5)	23 (56.1)
Severe (grade 6)	12 (16.0)	4 (5.2)	5 (14.3)	1 (2.8)	7 (17.5)	3 (7.3)

Plus-minus values are means ± SD.